Sign In
Buy BNTX
$88.45
-0.690 (-0.774%)
At Close: Jun 03, 2026
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
10:05am, Tuesday, 15'th Apr 2025
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
Vaccine stocks fall following FDA resignation
06:21pm, Monday, 31'st Mar 2025
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
02:41pm, Monday, 31'st Mar 2025
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
02:25pm, Monday, 31'st Mar 2025
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
10:13am, Monday, 31'st Mar 2025
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
07:25am, Monday, 31'st Mar 2025
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
01:36pm, Thursday, 20'th Mar 2025
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides compre
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
08:45am, Monday, 17'th Mar 2025
BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent rul
BioNTech SE (BNTX) Q4 2024 Earnings Call Transcript
12:14pm, Monday, 10'th Mar 2025
BioNTech SE (NASDAQ:BNTX ) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive O
BioNTech Stock Drops as Sales Outlook Disappoints
11:50am, Monday, 10'th Mar 2025
U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker's soft outlook for the year offset better-than-expected quarterly results.
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
10:06am, Monday, 10'th Mar 2025
BioNTech SE BNTX on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.
BioNTech Surpasses Q4 Revenue Estimates
08:42am, Monday, 10'th Mar 2025
Biopharmaceutical company BioNTech SE (BNTX -1.85%) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1.19 b
BioNTech guides for worse-than-expected 2025 revenue decline
07:35am, Monday, 10'th Mar 2025
German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion) and 2.2 billion euros, prompting a decline in its share pric
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
06:55am, Monday, 10'th Mar 2025
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
10:10am, Friday, 07'th Mar 2025
BioNTech SE BNTX will release its fourth-quarter financial results before the opening bell on Monday, March 10.
